HCV New Drugs

This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.

Risk Of Developing Liver Cancer After HCV Treatment

  • Home
  • Newly Diagnosed With Hep C? Or Considering Treatment?
  • All FDA Approved Drugs To Treat Hepatitis C
  • Hepatitis C Genotypes and Treatment
  • Mavyret (glecaprevir/pibrentasvir)
  • Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
  • Epclusa® (Sofosbuvir/Velpatasvir)
  • Harvoni® (Ledipasvir/Sofosbuvir)
  • VIEKIRA XR/VIEKIRA Pak
  • Zepatier(Elbasvir/Grazoprevir)
  • Cure - Achieving sustained virologic response (SVR) in hepatitis C
  • HCV Liver Fibrosis
  • FibroScan® Understanding The Results
  • HCV Cirrhosis
  • Staging Cirrhosis
  • HCV Liver Cancer
  • Risk Of Developing Liver Cancer After HCV Treatment
  • Treating Elderly HCV Patients
  • Fatty Liver Disease: NAFLD/NASH
  • Current research articles on ailments that may be related to HCV
  • Is There A Natural Way To Improve Liver Fibrosis?  
  • Can Food Or Herbs Interact With Conventional Medical Treatments?

Monday, September 17, 2018

HCV Next October Issue - Research continues to invalidate link between DAA treatment, liver cancer

HCV NEXT September/October Issue
Greetings, the following articles appeared in this months issue of HCV NEXT, published online over at Healio.

Table of Contents
HCV vaccine could reduce transmission in people who inject drugs

AASLD invests $4.06 million in liver disease research, development

Cover Story
HCV-Positive Organs: A Viable Option for Uninfected Transplant Patients

In the Journals
Research continues to invalidate link between DAA treatment, liver cancer

Novel ‘genotype 8’ surfaces among four patients with HCV

Treating HCV in prison ‘microenvironment’ reduces transmission

Heart transplant with HCV-positive organs successful, virus cleared

In the Journals Plus
Patients with chronic HBV die at younger age

Begin here....
Posted by HCV New Drugs at Monday, September 17, 2018
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
File Under donation, hbv, HCC during and after direct-acting antiviral therapy in patients with hepatitis C, HCV next, liver cancer, svr, transplant

No comments:

Post a Comment

Newer Post Older Post Home
Subscribe to: Post Comments (Atom)

https://feedburner.google.com/fb/a/mailverify?uri=HcvNewDrugsAndLiverHealth
View Feed

Subscribe 

  • ►  2020 (3)
    • ►  January (3)
  • ►  2019 (112)
    • ►  December (1)
    • ►  March (11)
    • ►  February (43)
    • ►  January (57)
  • ▼  2018 (689)
    • ►  December (18)
    • ►  November (87)
    • ►  October (62)
    • ▼  September (46)
      • Cardiovascular Risk Management and Hepatitis C: Co...
      • Are direct-acting antiviral agents for treatment o...
      • Hepatitis C Infection May Be a Blessing for Patien...
      • Hepatocellular carcinoma among US and non-US-born ...
      • Differences in hepatocellular carcinoma risk, pred...
      • Gilead Subsidiary to Launch Authorized Generics of...
      • Heavy drinkers and teetotalers alike may have heig...
      • Study: Damaged liver cells undergo reprogramming t...
      • Blood flow forces liver growth
      • Behind The Headlines: Older adults mixing prescrip...
      • How I Manage Low-Level Viremia in Patients Receivi...
      • Prevalence of occult hepatitis C virus infection i...
      • Editorial: interferon‐free DAAs are a great boon f...
      • What Is a Healthy Stool ?
      • Liquid biopsy shows promise for monitoring, detect...
      • Video: Recognizing Liver Cancer Risk Factors
      • Technology Drives Better HCV Outcomes
      • Alcohol abuse kills 3 million a year, most of them...
      • Hepatitis C Timeline - First recorded references t...
      • Cost-effectiveness analysis of treatment timing co...
      • Ultra-Short Treatment of Hepatitis C - Cocrystal P...
      • Overwhelming evidence shows hepatitis C treatment ...
      • Reconstructing healthy liver cells using a nanomat...
      • Louisiana developing ‘Netflix’ style subscription ...
      • Expand Screening for HCV infection in all adults l...
      • How Many Cases of Drug-Induced Liver Injury Are Ca...
      • Viking Therapeutics liver drug succeeds in mid-sta...
      • Audio Ask the Experts: Optimizing Cotreatment of H...
      • HCV Next October Issue - Research continues to inv...
      • Experimental nasal influenza vaccine tested in kid...
      • Children lose out on liver transplants, study finds
      • Psychological relief is the most important benefit...
      • Treatment of Chronic HCV: Patients’ experiences be...
      • Gilead targets hep B in half a billion dollar deal...
      • Chronic Hepatitis C Patients with Obesity: Do we N...
      • Hepatitis C; Does the old-fashioned sofosbuvir plu...
      • Hepatitis C virus prevalence and estimated inciden...
      • Greg Jefferys: Purchasing Hep C Generics
      • Neuropsychiatric symptoms associated with hepatiti...
      • Hepatitis C - Generic sofosbuvir-based interferon-...
      • Epclusa® (Sofosbuvir/Velpatasvir) with or without ...
      • Hepatitis C virus genotype 3: clinical features, c...
      • Groups call for end to Gilead’s hepatitis C drug m...
      • Unapproved kratom products: FDA issuing new warnin...
      • HCV Newsletters & Updates: Obesity in liver diseas...
      • Risk of Liver Cancer in Patients with NAFLD
    • ►  August (36)
    • ►  July (23)
    • ►  June (44)
    • ►  May (60)
    • ►  April (103)
    • ►  March (85)
    • ►  February (59)
    • ►  January (66)
  • ►  2017 (898)
    • ►  December (42)
    • ►  November (56)
    • ►  October (104)
    • ►  September (81)
    • ►  August (74)
    • ►  July (90)
    • ►  June (52)
    • ►  May (53)
    • ►  April (105)
    • ►  March (94)
    • ►  February (85)
    • ►  January (62)
  • ►  2016 (525)
    • ►  December (15)
    • ►  November (73)
    • ►  October (43)
    • ►  September (53)
    • ►  August (41)
    • ►  July (42)
    • ►  June (28)
    • ►  May (54)
    • ►  April (60)
    • ►  March (37)
    • ►  February (40)
    • ►  January (39)
  • ►  2015 (546)
    • ►  December (27)
    • ►  November (53)
    • ►  October (46)
    • ►  September (41)
    • ►  August (42)
    • ►  July (24)
    • ►  June (49)
    • ►  May (53)
    • ►  April (59)
    • ►  March (59)
    • ►  February (37)
    • ►  January (56)
  • ►  2014 (613)
    • ►  December (29)
    • ►  November (64)
    • ►  October (62)
    • ►  September (17)
    • ►  August (51)
    • ►  July (28)
    • ►  June (38)
    • ►  May (73)
    • ►  April (87)
    • ►  March (60)
    • ►  February (45)
    • ►  January (59)
  • ►  2013 (957)
    • ►  December (44)
    • ►  November (77)
    • ►  October (71)
    • ►  September (71)
    • ►  August (73)
    • ►  July (84)
    • ►  June (86)
    • ►  May (78)
    • ►  April (110)
    • ►  March (70)
    • ►  February (79)
    • ►  January (114)
  • ►  2012 (1293)
    • ►  December (80)
    • ►  November (114)
    • ►  October (114)
    • ►  September (95)
    • ►  August (100)
    • ►  July (120)
    • ►  June (125)
    • ►  May (145)
    • ►  April (134)
    • ►  March (88)
    • ►  February (64)
    • ►  January (114)
  • ►  2011 (1574)
    • ►  December (75)
    • ►  November (81)
    • ►  October (70)
    • ►  September (83)
    • ►  August (142)
    • ►  July (157)
    • ►  June (166)
    • ►  May (128)
    • ►  April (160)
    • ►  March (176)
    • ►  February (140)
    • ►  January (196)
  • ►  2010 (672)
    • ►  December (184)
    • ►  November (236)
    • ►  October (223)
    • ►  September (29)

Labels

(Sofosbuvir) now Sovaldi 2017 Digestive Disease Week 2017 EASL-AASLD joint meeting on Alcohol related Liver Disease 2017 World Hepatitis Summit 2017 - International AIDS Society (IAS) 2017 British and Irish Gastroenterology meeting 2017 CROI 2017 Conference on Retroviruses and Opportunistic Infections (CROI) 2017 Drug-Induced Liver Injury Conference 2017 EASL Clinical Practice Guidelines on the management of hepatitis B virus infection 2017 GUIDE TO HEPATITIS C TESTING 2017 Gastroenterological Society of Australia Australian Gastroenterology Week 2017 IDWeek 2017 International Conference on Viral Hepatitis (ICVH) 2017 International Liver Cancer Association Annual Conference 2017 International Liver Congress 2017 International Liver Transplantation Society Consensus Statement on Hepatitis C Management in LT Candidates 2017 Practice update for managing patients cured of HCV infection 2017 Summary International Liver Congress 2017 TAG Pipeline Report 2017 The 68th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2017 2017 World Hepatitis Day 2017-10th Paris Hepatitis Conference 2017-APASL 2017-Hepatitis A to E 2017-National Strategy for the Elimination of HBV HCV 2017-WHO Essential Medicines List 2017-World Hepatitis summit 2017/WHO Global hepatitis report 2017/WHO guidelines on testing for chronic HBV and HCV infection 2018 2018 - Eliminating Hepatitis C in England 2018 - Conference on Retroviruses and Opportunistic Infections (CROI) 2018 - International Liver Congress 2018 - adult 2018 - updated and evidence-based review about Hepatocellular Carcinoma 2018- 11th Paris Hepatology Conference 2018-Diagnosis & management of hepatitis C infection 2018-WHO Access to hepatitis C treatment AASLD 2017 updated hepatitis C practice guidelines AL-335 Acetaminophen Safety Adherence to therapy BCX5191 Bavituximab Behind the Headlines Big Pharma Brain CC-31244 CDC COPD Canada Colloidal silver Complementary and Alternative Medicine Counterfeit drugs Cryoglobulinemia Daklinza(Daclatasvir) Daklinza(Daclatasvir) with sofosbuvir Dental Depression Digestion Drug Assistance Programs Epclusa® Epclusa® (Sofosbuvir/Velpatasvir) FDA Fatigue-Cognitive Function-Sleep Quality Fatty Liver Fatty Liver-RP103 Fatty liver CF102 Foodborne illness GS-7977 now Sofosbuvir GS-7977 now Sofosbuvir and simeprevir (TMC435) GS-7977 now Sofosbuvir Plus Riba GS-7977 now Sofosbuvir off label use GS-7977 now Sofosbuvir-FDA Review GS-7977 now Sofosbuvir/BMS-790052 now Daclatasvir GS-7977 now sofosbuvir / GS-5885 now ledipasvir Generic sofosbuvir-based Glecaprevir/Pibrentasvir Grazoprevir/Elbasvir (MK-5172/MK-8742) plus sofosbuvir HALT-C HBV/HCV dual infection HCC during and after direct-acting antiviral therapy in patients with hepatitis C HCV Australia HCV Awareness HCV Awareness-screening strategies HCV Baby Boomers HCV News-monthly rewind HCV News-weekly rewind HCV Self-management HCV Vaccine HCV Vaccine-TG4040 (MVA-HCV) HCV Worldwide HCV Worldwide Asia Australia Egypt HCV Worldwide-Egypt HCV Worldwide-Europe Canada Israel HCV agents/drug interactions HCV cardiovascular disease HCV diet HCV generics HCV next HCV pregnancy HCV research HCV symptoms HCV tests HCV transmission FAQ HCV vaccine GI-5005 HCV-Editorial HCV-Education HCV-Insulin resistance HCV-Statins HCV-elderly HCV/HBV/HIV special populations HEV HIV HIV-children HIV/HCV Harvoni patient assistance Harvoni® (Ledipasvir/Sofosbuvir) Healthy you History of HCV IL28B IV drug use Investment News HCV Drugs Joint pain Lichen Planus Liver Abscess Liver Cancer Treatment Liver Cysts Liver Fibrosis Liver Injury Dietary Supplements Liver Pain MAVIRET (glecaprevir/pibrentasvir) MK3(MK-3682/grazoprevir/ruzasvir1) Mavyret (glecaprevir/pibrentasvir) Medicaid Mediterranean diet Memorial Wall Men and HCV Milk thistle Miracle Mineral Solution-MMS Miravirsen Morbidity-SVR Mortality Mother to a Child Transmission Muscle Cramps NSAID Neutropenia HCV Treatment Nonalcoholic Steatohepatitis (NASH) OLYSIO™ (Simeprevir) and Sovaldi (Sofosbuvir) OLYSIO™(Simeprevir) containing regimens OTHER INFECTIOUS DISEASE Origin Of Hepatitis Other Conditions Related To HCV Other Conditions Related To HCV-Vasculitis Other Health News PHYSICAL FINDINGS SUGGESTIVE OF CIRRHOSIS Pediatric liver disease Pharmaceuticals Porphyria Cutanea Tarda (PCT) Post Treatment Post Treatment Symptoms Questions About HCV Rebuttal over Cochrane Review of DAAs SPONTANEOUS CLEARANCE STAT-C SVR24-SVR12-SVR4 Seasonal Flu Vaccine Simeprevir Simeprevir and Daclatasvir Simeprevir now Olysio Simeprevir now Olysio FDA Approved Simeprevir now Olysio and Daclatasvir Small fiber neuropathy Sofosbuvir/Cost Sorafenib Sovaldi resistance Starting HCV Treatment Surgery in liver disease TGIF-News Review Tamiflu Tattoos Technivie The natural history of hepatitis C Timeline Hepatitis Treat All VIEKIRAX Veterans Affairs Viekira Pak Viekira Pak Prescribing Information Viekira XR Vitamin E-TE/TCP supplements Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) addiction alcohol consumption anemia antidepressants arthritis ascites bath salts-spice blood scandal cancer children treating HCV chronic fatigue chronic liver failure chronic pain cirrhosis cirrhosis-Vibrio vulnificus-raw oysters cirrhosis-complications clinical trials coffee colonoscopy compensated cirrhosis decompensated cirrhosis diabetes diabetes-insulin resistance disease progression donation encephalopathy endoscopy fatigue fibromyalgia gallstones geno1 geno2 geno3 geno4 geno5 geno6 genotype test genotypes mixed genotypes;All grazoprevir/MK-8408/MK-3682 grazoprevir/elbasvir (MK-5172/MK-8742) grazoprevir/elbasvir / MK-3682 green tea hav hav vaccine hbv hbv vaccine hepatologist herb herb-kava hiv/hbv-coinfection kratom liver biopsy liver cancer liver cancer treatment-radiofrequency ablation (RFA) liver cancer/sorafenib liver disease liver function tests liver health liver/anatomy lymphoma marijuana medical tourism melatonin mental health miRNAs newly diagnosed newsletters noninvasive tests for fibrosis nonresponders null responders ombitasvir/paritaprevir/ ritonavir (OBV/PTV/r) opioid addiction partial responders platelets probiotics procrit rash recall regeneration regenerative Medicine relapse resistance to protease inhibitors response-guided therapy restless legs syndrome ribavirin salt selenium side effects side effects-direct-acting antivirals silibinin silymarin sphincter of Oddi spleen stem cell tourism stem cells stigma supplements support support-hotline svr svr durability thyroid toxicity transmission transmission-needlestick transplant transplant-MELD tylenol upper abdominal pain varices veterans video viral load vitamin A vitamin B12 vitamin D vitamin E vitamin k vitamins weekend reading wellness women zinc

Search This Blog

Contact hcvnewdrugs@gmail.com

Helpful Links
HCV Education
Research Articles
Fibrosis
Cirrhosis
Liver Cancer
Liver Transplants
Fatty Liver Disease
HCV-elderly
Possible Side Effects Of HCV Therapy
Other Conditions Related To HCV
HCV Genotypes/treatment
HCV Newsletters
Premier Hepatitis C Websites

The above links offer data about interferon-free regimens approved to treat HCV, with learning activities,  editorials, and tips from patient bloggers who understand the ups and downs of liver disease, in addition to a list of outstanding hepatitis C websites, blogs and support forums.

On Twitter
I highly suggest you follow Henry E. Chang on Twitter if you are interested in reading articles about the treatment and management of hepatitis C.

The controversy over expensive new drugs for hepatitis C
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"
Latest Update Feb 12, 2019 
Lancet Study: 
Direct-acting antivirals reduce risk of premature mortality and liver cancer for people with chronic hepatitis C 
These findings firmly counter those of a Cochrane review of direct-acting antiviral treatment trials that could neither confirm nor reject if direct-acting antivirals had an effect on long-term HCV-related morbidity and mortality. They also provide the best evidence to date to support guidance documents that recommend direct-acting antiviral treatment for all patients with chronic HCV infection.

The Controversy 
Rebuttal over Cochrane Review of DAAs 
A systematic review published by the Cochrane Collaboration suggested achieving SVR (cure) for patients using hepatitis C direct-acting antivirals (DAAs) doesn't correlate with any long term benefits. View each rebuttal and all ongoing media coverage.

Simple theme. Powered by Blogger.

FAIR USE NOTICE:

If this site contains copyrighted material the use of which has not been specifically authorized by the copyright owner, it is being made available in an effort to advance the understanding of the ethics dealing with medical practice, medical care, new drug research, drug trials, science and scientific research, human rights, social justice and, in addition, the law and politics which cover these areas.

It is believed that this use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed to visitors of this “HCV New Drugs Blog” without profit to the blog or to those who by visiting this blog have expressed interest in receiving the included information for research and educational purposes.

The material in this site is provided for educational and informational purposes only, and is not intended to be a substitute for a health care provider's consultation. Please consult your own appropriate health care provider about the applicability of any opinions or recommendations with respect to your own symptoms or medical conditions. The information on this site does not constitute legal or technical advice